Is XRP About to Rocket After Tomorrow’s FOMC Meeting? Here’s What You Missed!

But let’s not get too excited just yet. The rate cut will still depend on inflation numbers, labour data, and whether the economy feels like being cooperative. Since the last cut in September 2024, the US dollar made a dramatic leap, while the crypto market experienced some very brief but entertaining jolts. We’ll see if lightning strikes again. ⚡

Second Line Capital’s Conservative Gambit in Short Maturity ETFs

According to a filing with the Securities and Exchange Commission dated Nov. 18, Second Line Capital, LLC initiated a new position in First Trust Enhanced Short Maturity ETF (FTSM 0.01%) by acquiring 120,501 shares. The estimated value of the new holding was $7.2 million at quarter-end, based on SEC-reported data. The addition represents 1.5% of the fund’s 13F reportable assets under management. A decision as unassuming as a well-tailored overcoat-practical, yet evoking admiration for its understated elegance.

Biotech Fund’s $22M Bet on Pharvaris – Is It a Buy?

The SEC filing read like a treasure map, marking Pharvaris N.V. (PHVS) as the X that marks the spot. Saturn V, with its $456 million under management, now holds 17 U.S. equities, and PHVS claims 4.9% of their assets like a barn cat claiming the porch. The fund’s top holdings-ABVX, AMLX, JAZZ-read like a list of names from a saloon’s ledger, each with a hefty chunk of the pie. But PHVS? That’s the new kid with a grin and a stack of papers that smell of hope and bradykinin B2-receptors.

Will the Fed Crash Bitcoin (BTC) or Spark a $100K Rally?

Crypto sorcerer Michaël van de Poppe says Bitcoin is still galloping along its bullish path. He’s eyeing the $91,892 mark like a hawk. Break that, and the next hurdle is $100,793. Push past that and-hold your breath-$100,000 could be in sight by December’s end. 🎯

Capital’s Enigmatic Gambit: Dyne Therapeutics

According to the sacred scrolls of the SEC, filed for the period ending September 30, Saturn V Capital Management LP augmented its stake in Dyne Therapeutics by approximately 1.2 million shares. The fund’s position now commands a value of $33.8 million, a sum that, in the realm of 13F reportable assets, ranks as the fourth-largest in its portfolio. One might imagine the fund’s managers, like scribes in a cathedral of commerce, meticulously inscribing this act into the annals of fiscal history.

BTC Dumps to $90K, HYPE Crashes 9%-What’s Next? 🚀💥

Bitcoin started the week with a “I’m gonna be a big boy today!” vibe, hitting $92K, but then… sigh… the bears came in with a “You’re not as cool as you think” punch. Now it’s chilling at $90,200. Because nothing says “confidence” like a 2% dip. 📉